SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

The Trade Desk, Inc. engages in the provision of a self-service and cloud-based ad-buying platform. The firm operates through the following geographical segments: United States and International. It offers omnichannel advertising, audience targeting, solutions for identity, application programming interface (API), custom, and programmatic, measurement and optimization. The company was founded by Jeffrey Terry Green and David Pickles in November 2009 and is headquartered in Ventura, CA.

Trade Desk Inc - Ordinary Shares - Class A

Trade Desk Inc

The Trade Desk is facing intense sell-side pressure following a significant revenue miss and weak third-quarter guidance that signaled a major growth slowdown. The community is sharply divided, with frustrated retail investors expressing deep anger toward management's performance while some see a potential long-term value play in the stock's sharp valuation reset.

Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

Iovance Biotherapeutics is trending after reporting record quarterly revenue that significantly exceeded guidance, driven by accelerating adoption of Amtagvi and improved manufacturing efficiencies. The community is buzzing over management's bullish commentary regarding their lung cancer trial, which they suggest may show durable results comparable to their melanoma success, alongside optimism that the company is emerging as a leader in a scalable, high-barrier-to-entry cell therapy market.

Applied Optoelectronics, Inc. engages in the design and manufacture of optical communications products. Its products include optical devices, such as laser diodes, photodiodes, related modules and circuitry, and equipment for applications in fiber-to-the-home, cable television, point to point communications, and wireless. The company was founded by Chih Hsiang Lin on February 28, 1997 and is headquartered in Sugar Land, TX.

Applied Optoelectronics Inc

Applied Optoelectronics is experiencing a surge in trading activity driven by reports that the U.S. government is considering restrictions on Chinese-made optical transceivers, a move that could significantly benefit domestic manufacturers with U.S.-based capacity. Investors are closely monitoring the stock ahead of its upcoming earnings report, with community discussions largely focused on whether the company can successfully scale its production ramp to meet robust demand from AI hyperscalers.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

AppLovin is facing extreme volatility after reporting a slight revenue miss and softer-than-expected Q3 guidance, despite delivering significant year-over-year growth and strong cash flow. The community is sharply divided, with many investors labeling the sell-off a classic overreaction and a long-term buying opportunity, while others express concern over plateauing gaming growth and increased competition in AI-driven advertising.

Atlassian Corp. is a holding company, which engages in providing team collaboration and productivity software. Its products include Jira Software, Confluence, Jira Service Management, and Loom. The company was founded by Michael Cannon-Brookes and Scott Farquhar in October 2002 and is headquartered in San Francisco, CA.

Atlassian Corporation - Ordinary Shares - Class A

Atlassian Corporation Plc

Atlassian is trending as its latest earnings report delivered significant revenue and cloud growth that defied prevailing fears of a 'SaaS apocalypse' driven by AI disruption. The community is actively discussing the stock's massive after-hours move, with bulls celebrating a potential short squeeze and shifting sentiment around the company's long-term cloud momentum, while some remain cautious about valuation and persistent GAAP losses.

Cloudflare, Inc. engages in the provision of cloud-based services to secure websites. The firm offers various products for application security, performance and reliability, network services, Zero Trust, developer platform, media delivery, insights, domain registration, and consumer services. It operates through the United States and Rest of the World geographical segments. The company was founded by Matthew Prince, Michelle Zatlyn, and Lee Holloway in July 2009 and is headquartered in San Francisco, CA.

Cloudflare Inc - Ordinary Shares - Class A

Cloudflare Inc

Cloudflare stock is currently the focus of significant community debate following a mixed earnings reaction where shares surged after beating expectations and raising guidance, despite ongoing scrutiny over the company's profitability and workforce restructuring. Investors are actively discussing the firm's role in the 'agentic internet' infrastructure and whether its aggressive expansion in AI-driven cloud networking justifies its current valuation.

Sezzle, Inc. engages in the operation of a digital payment platform that enables bank-to-bank transfer of money between consumers and businesses. The company was founded by Charlie G. Youakim, Killian Brackey and Paul V. Paradis on January 4, 2016 and is headquartered in Minneapolis, MN.

Sezzle Inc.

Sezzle is seeing significant volatility as market participants react to a stellar quarterly earnings report that beat expectations, even as the stock faces short-term pressure from profit-taking and ongoing legal investigations. While retail traders are actively debating whether to capitalize on the pullback or hold for long-term growth, the community is closely watching the company's aggressive share buyback plan and a high short interest, which many see as potential fuel for a future squeeze.

Serve Robotics, Inc. engages in providing self-driving delivery. It designs, develops, and operates zero-emissions robots that serve people in public spaces, starting with food delivery. The company was founded by Ali Kashani, Dmitry Demeshchuk and MJ Burk Chun in 2017 and is headquartered in Redwood City, CA.

Serve Robotics Inc

Serve Robotics is trending due to heightened volatility and significant call option activity as investors speculate on a potential short squeeze or buyout, despite ongoing concerns over cash burn and reduced revenue guidance. Community sentiment is deeply divided, with some investors betting on the long-term potential of physical AI and delivery expansion, while others are frustrated by recent downward price pressure and the company's fiscal outlook.

DraftKings, Inc. is a digital sports entertainment and gaming company, which engages in the provision of online sports betting, online casino, daily fantasy sports product offerings, DraftKings Marketplace, retail sportsbook, media, and other consumer product offerings. The company was founded by Jason D. Robins, Matthew Kalish, and Paul Liberman on December 31, 2011 and is headquartered in Boston, MA.

DraftKings Inc. - Ordinary Shares - Class A

DraftKings Inc

DraftKings is facing significant volatility and investor scrutiny ahead of its Q2 earnings report, with the community polarized between those betting on long-term growth driven by prediction markets and those concerned about increased sector competition and disappointing recent sector performance. Discussion remains highly heated, with persistent debate over management's effectiveness, the impact of promotional spending on revenue, and the company's ability to maintain guidance through the upcoming football season.

Roku, Inc. engages in the provision of a streaming platform for television. It operates through the following segments: Platform and Devices. The Platform segment includes the sale of digital advertising and distribution of streaming services. The Devices segment is involved in the sale of streaming players, Roku-made televisions, smart home products and services, audio products, and related accessories. The company was founded by Anthony J. Wood in October 2002 and is headquartered in San Jose, CA.

Roku Inc - Ordinary Shares - Class A

Roku Inc

Roku is experiencing significant market attention following rumors of a potential buyout, which has driven high trading volume and volatility. Investors are actively debating the legitimacy of the takeover reports and speculating on potential suitors while closely monitoring the stock's performance ahead of its upcoming S&P MidCap 400 inclusion.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Zymeworks Inc. (ZYME) Reports Q2 Loss, Beats Revenue Estimates

Zymeworks (ZYME) delivered earnings and revenue surprises of -10.71% and +25.41%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q2 Loss, Tops Revenue Estimates

Rhythm Pharmaceuticals (RYTM) delivered earnings and revenue surprises of +9.88% and +6.18%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Lipocine Appoints Michael J. Grissinger to Board of Directors

Lipocine Appoints Michael J. Grissinger to Board of Directors Lipocine Appoints Michael J. Grissinger to Board of Directors PR Newswire SALT LAKE CITY, Aug. 3, 2026 SALT LAKE CITY, Aug. 3, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary...

Aprea Therapeutics (APRE) Upgraded to Buy: Here's What You Should Know

Aprea Therapeutics (APRE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Aprea Therapeutics Stock Rises After Company Reports Second Unconfirmed Case Of Tumor Reduction In Trial

Equity

The company reported a second unconfirmed partial response in a patient with advanced endometrial cancer being treated at the 220 mg dose level.


Aprea Therapeutics Advanced Cancer Trial Shows Promising Results, Stock Soars

Aprea Therapeutics shares rise after promising Phase 1 trial results with APR-1051 in cancer treatment.read more...

New Strong Sell Stocks for January 19th

APRE, NFE and CZR have been added to the Zacks Rank #5 (Strong Sell) List on January 19, 2026.

 New Strong Sell Stocks for Jan. 14

APRE, CULP and PSKY have been added to the Zacks Rank #5 (Strong Sell) List on Jan.13, 2026.

Marc Duey Acquires 21,459 Shares of Aprea Therapeutics (NASDAQ:APRE) Stock

Aprea Therapeutics, Inc. (NASDAQ:APRE - Get Free Report) Director Marc Duey purchased 21,459 shares of the firm's stock in a transaction on Wednesday, December 10th. The shares were acquired at an...

Aprea is a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers. The Company is pioneering a new approach to treat cancer by exploiting vulnerabilities associated with cancer cell mutations. This approach was developed to kill tumors while minimizing the effect on normal, healthy cells. Aprea’s technology has potential applications across multiple cancer types, enabling it to target a range of tumors, including ovarian, endometrial, colorectal and head and neck squamous cell carcinoma. The Company’s lead programs are APR-1051, an oral, small-molecule inhibitor of WEE1 kinase, and ATRN-119, a small molecule ATR inhibitor, both in clinical development for solid tumor indications.

Aprea Therapeutics Inc

Neutral Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Fundamentals

Info